ibandronic acid has been researched along with Kidney Diseases in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angst, R; Caspar, CB; Inauen, R; Schmieding, K; Steiner, R; Thürlimann, B; von Moos, R | 1 |
| Jonkanski, I; Mautalen, C; Miller, PD; Ragi-Eis, S; Ramirez, F | 1 |
| Atzpodien, E; Bauss, F; Pfister, T | 1 |
| Hirschberg, R | 1 |
| Diel, IJ; Pecherstorfer, M | 1 |
| Bergstrom, B; Body, JJ; Diel, IJ; Tripathy, D | 1 |
| Buckley, JR; Price, PA; Williamson, MK | 1 |
1 review(s) available for ibandronic acid and Kidney Diseases
| Article | Year |
|---|---|
Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Infusions, Intravenous; Injections, Intravenous; Kidney Diseases | 2004 |
3 trial(s) available for ibandronic acid and Kidney Diseases
| Article | Year |
|---|---|
Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes.
Topics: Adult; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Kidney; Kidney Diseases; Longitudinal Studies; Middle Aged; Treatment Outcome | 2010 |
Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease--the DIVINE study.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Endpoint Determination; Female; Glomerular Filtration Rate; Humans; Ibandronic Acid; Injections, Intravenous; Kidney Diseases; Kidney Function Tests; Osteoporosis, Postmenopausal; Risk Factors | 2011 |
Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results.
Topics: Adolescent; Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Kidney Diseases; Middle Aged; Time Factors | 2006 |
3 other study(ies) available for ibandronic acid and Kidney Diseases
| Article | Year |
|---|---|
The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats.
Topics: Acetylglucosamine; Animals; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Female; Glutathione Transferase; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Kidney Diseases; L-Lactate Dehydrogenase; Rats; Rats, Wistar; Urea; Zoledronic Acid | 2003 |
Nephrotoxicity of third-generation, intravenous bisphosphonates.
Topics: Animals; Diphosphonates; Ibandronic Acid; Imidazoles; Injections, Intravenous; Kidney Diseases; Kidney Tubules, Proximal; Rats; Zoledronic Acid | 2004 |
The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats.
Topics: Animals; Calcinosis; Diphosphonates; Heart Valve Diseases; Ibandronic Acid; Kidney Diseases; Lung Diseases; Male; Rats; Rats, Sprague-Dawley; Vitamin D | 2001 |